ABIVAX (EPA:ABVX) | WebDisclosure

PRESS RELEASE

published on 01/23/2025 at 22:05, 1 year 6 months ago

Abivax annonce la présentation de sept abstracts sur l'utilisation d’Obefazimod dans le traitement de la rectocolite hémorragique lors de l’édition 2025 du 20e congrès annuel de la ECCO
Abivax annonce la présentation de sept abstracts sur l'utilisation d’Obefazimod dans le traitement de la rectocolite hémorragique lors de l’édition 2025 du 20e congrès annuel de la ECCO

Abivax Obefazimod Rectocolite Hémorragique ECCO Congrès
PRESS RELEASE

published on 01/23/2025 at 22:05, 1 year 6 months ago

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
Abivax announces presentation of seven abstracts for Obefazimod in ulcerative colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Abivax Obefazimod Ulcerative Colitis Clinical Trials ECCO
PRESS RELEASE

published on 01/09/2025 at 17:44, 1 year 6 months ago

Abivax franchit une étape clé dans le recrutement de l’essai de phase 3 ABTECT
Abivax franchit une étape clé dans le recrutement de l'essai de phase 3 ABTECT pour le traitement de la RCH. Objectif de recrutement proche de 82%. Premiers résultats attendus en 2025

Abivax Recrutement Phase 3 ABTECT RCH
BRIEF

published on 01/09/2025 at 17:40, 1 year 6 months ago

Abivax Reaches Key Enrollment Milestone in Phase 3 ABTECT Trial

Abivax Obefazimod Ulcerative Colitis Phase 3 Trial Clinical Results
BRIEF

published on 01/09/2025 at 17:40, 1 year 6 months ago

Abivax franchit une étape clé dans le recrutement de l'essai de phase 3 ABTECT

Abivax Obefazimod Rectocolite Hémorragique Essai De Phase 3 Résultats Cliniques
PRESS RELEASE

published on 01/09/2025 at 17:35, 1 year 6 months ago

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
Abivax achieves key milestone in Phase 3 ABTECT trial enrollment with 82% of target participants enrolled for evaluating obefazimod in ulcerative colitis, aiming for NDA submission by H2 2026

Abivax Obefazimod Ulcerative Colitis Phase 3 ABTECT Trial
BRIEF

published on 12/23/2024 at 22:10, 1 year 7 months ago

Abivax Announces Board Resignation

Abivax Obefazimod Board Resignation Truffle Capital Philippe Pouletty
BRIEF

published on 12/23/2024 at 22:10, 1 year 7 months ago

Abivax annonce la démission de son conseil d'administration

Abivax Obefazimod Démission Du Conseil D'administration La Capitale De La Truffe Philippe Pouletty
PRESS RELEASE

published on 12/23/2024 at 22:05, 1 year 7 months ago

Abivax annonce une modification de la composition de son Conseil d'administration
Abivax annonce la démission du Dr Philippe Pouletty en tant qu'administrateur et recherche un nouveau membre du Conseil d'administration. Plus d'informations sur www.abivax.com

Abivax Conseil D'administration Rectocolite Hémorragique Démission Maladies Inflammatoires
PRESS RELEASE

published on 12/23/2024 at 22:05, 1 year 7 months ago

Abivax annonce une modification de la composition de son Conseil d'administration
Abivax annonce la démission du Dr. Philippe Pouletty en tant qu'administrateur et recherche un nouveau membre du Conseil d'administration pour soutenir le développement de thérapies. Détails sur www.abivax.com

Innovation Abivax Conseil D'administration Démission Thérapies

Published on 08/07/2026 at 00:45, 9 hours 36 minutes ago

NXT Energy Solutions Announces Second Quarter 2026 Results
Published on 08/06/2026 at 23:15, 11 hours 6 minutes ago

LNG Energy Group Announces Issuance of Second Partial Revocation Order and Further Details on Private Placement Financing
Published on 08/06/2026 at 22:15, 12 hours 6 minutes ago

Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada
Published on 08/06/2026 at 22:05, 12 hours 16 minutes ago

Innodata Reports Record Second Quarter 2026 Results
Published on 08/06/2026 at 22:00, 12 hours 21 minutes ago

Gold Terra Announces Closing of Second Tranche of the C$10.8M LIFE

View all ACCESSWIRE

Published on 08/07/2026 at 10:17, 4 minutes ago

Cantourage welcomes clarification on the implementation of the German GKV-FinStG
Published on 08/07/2026 at 09:05, 1 hour 16 minutes ago

ROHM's New 2nd-generation Terahertz Wave Oscillation Device Delivers 4 Times Higher Output Power
Published on 08/07/2026 at 09:05, 1 hour 16 minutes ago

FAMILIARITÉ: A Poetic Convergence of Cinema and Literature
Published on 08/07/2026 at 09:05, 1 hour 16 minutes ago

Coway Announces Financial Results for Q2 FY2026
Published on 08/07/2026 at 09:01, 1 hour 20 minutes ago

Original-Research: GFT Technologies SE (von NuWays AG): BUY

View all EQS

Published on 08/07/2026 at 08:30, 1 hour 51 minutes ago

Disclosure of shares outstanding and voting rights - 07.08.2026
Published on 08/07/2026 at 08:30, 1 hour 51 minutes ago

Déclaration nombre d'actions et droits de vote - 07.08.2026
Published on 08/06/2026 at 18:26, 15 hours 55 minutes ago

Air Liquide voting rights as of July 31st 2026
Published on 08/06/2026 at 18:26, 15 hours 55 minutes ago

Air Liquide droits de vote au 31 juillet 2026
Published on 08/06/2026 at 17:46, 16 hours 35 minutes ago

Déclaration des droits de vote à fin juillet 2026

View all LES ECHOS COMFI WIRE

News